Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Emisphere Technologies has announced that Novartis Pharma has finished recruitment for a multi-center Phase III study exploring the safety and efficacy of Salmon Calcitonin and Emisphere's proprietary Eligen technology in the treatment of vertebral fractures in postmenopausal women aged 60-80 with osteoporosis.
Subscribe to our email newsletter
The last of around 4,500 patients was recruited in the final week of June 2008, and the three-year study will be conducted in North and South America, Europe and Asia.
Michael Novinski, president and CEO of Emisphere, said: “This Phase III study provides yet another application of our Eligen technology in the fight against osteoporosis. Safe, effective and rapid treatment will make a difference in the lives of millions of American women who are afflicted with the disease.”